AVAX Technologies Inc (AVXT)

[johnny canuck]

Thank's Bayetta.
A few highlights from the website.
MVax® for the Treatment of Melanoma
AVAX's Phase III Study
AVAX plans to launch an International Phase III Registration trial with its lead product MVax® by the end of the year. The Phase III study will enroll approximately 400 patients. AVAX has met with the United States Food and Drug Administration ("FDA") on the study design and has plans to continue to work with FDA to be able to focus and re-launch this pivotal clinical study.

The protocol will be based on published data showing that administration of MVax® alone can induce clinically meaningful anti-tumor responses in patients with stage III and IV melanoma.